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of every person, a sense of justice and impartiality being its
guiding principles. Access is the establishment of communica-
tion to obtain information or use of available resources. There-
fore, from the social perspective, equity of access means equal
rights to information and available resources.
For equity of access to be attainable in Latin America or any
other global region, it is necessary to take into account some
fundamental principles that aim to ensure a health system is
appropriate given the social, political, epidemiologic, and eco-
nomic environment of its region.
The establishment of a health budget should be linked to
population necessities and regularly revised; decisions about
health priorities should be based on necessities with a sufficient
health care services structure that is effectively equipped to
answer the health demand generated by the identification of
these necessities, and based on coherent legislation supporting
the decisions established in the health care arena.
Coherent and humane treatment, as well as knowledge of a
population’s specific health reality, cultural issues, and health
necessities are also fundamental requisites to be taken into ac-
count to transform the concept of equity of access into some-
thing attainable.
Access to health care, although it has to do with the same
fundamental principle, varies depending on the perspective by
which it is evaluated. From a patient’s perspective, access is to
have his/her treatment delivered in the best way, with the best
therapeutic options, and at the lowest possible cost—or at no
cost through a public health care system. From a physician’s
perspective, access to health care means service for all patients
in a way that meets their treatment needs. For medical devices
manufacturers, to improve access means to provide the market
with innovative technologies that could benefit patients’ health
results.
In this article, analyses developed by specialists in equity of
access to health care in Argentina, Brazil, Colombia, and Mexico
are presented.
Argentina
The Argentine health system is tripartite: public, social insur-
ance, and private. The first guarantees universal health care for
nearly 16 million people through primary care centers and hos-
pitals (although these services are used mainly by persons in
lower income groups). This sector is financed mainly through
taxes but users can be asked for aminimal fee for service. A very
important free provision of drugs program operates through
these providers. The social insurance sector comprises more
than 300 institutions formed mainly by labor unions organized
at national and subnational levels covering nearly 17 millionConflicts of interest: The authors have indicated that they have nopeople. Health coverage level is fixed by law in the Mandatory
Medical Program (PMO). This sector is financed by compulsory
contributions made by employees (3%) and employers (6%). Fi-
nally, the private sector is mainly financed through organized
prepaid medical plans, and covers about 3.2 million people.
These operate similarly to social insurance, using PMO as a ref-
erence standard of minimum level of coverage.
National health policy regarding drugs rests on several top-
ics. Since 2002 a national law has mandated the prescription of
pharmaceuticals by their generic name; the objectives of this
policy are to improve quality of prescriptions and promote price
competition. Also, Argentina has several national programs
providing free medicines. REMEDIAR and other free provision
programs are highly centralized, achieving important purchas-
ing power in the prices of many drugs (i.e., antiretroviral ther-
apy). Finally, the health authority describes different levels on
the financial coverage of health care in the PMO. For drugs, this
means 40% coverage for 178 commonly used drugs, 70% cover-
age for 112 drugs prescribed for chronic conditions, and 100%
coverage of drug costs in some particular cases such as insulin,
cancer, and tuberculosis drugs.
Two nationally representative surveys are useful when ana-
lyzing the health care access issue in terms of utilization and
expenditures in Argentina. The National Expenditures Survey
(NES) 2005 and the Health Care Utilization and Expenditure Sur-
vey (HCUES) 2005. Using NES to construct standardized figures
for the share of health expenditure in total household expendi-
ture and for the presence of health coverage across income
quintiles, one can find a regressive pattern for the first indicator
(15% for the poorest quintile, 11% for the richest quintile) and
also an inverse relationship with health coverage (50% for the
poorest, 89% for the richest).
There are some interesting points derived from HCUES in
relation to the access problem for ambulatory consultations
across income quintiles. Although there were no important dif-
ferences on the utilization rate (near 40%), there were differ-
ences on the proportion of people who pay for the access (17%
for the poorest, 41% for the richest). This reflects a nonregres-
sive pattern on consultations. Also, one can find a remarkable
selection pattern that indicates that for any socioeconomic con-
dition there is always a place where one can find health care
services. Regarding hospitalizations, HCUES shows that poor
people are more frequently hospitalized than other groups and
often without paying a fee. There is not a clear trend for drug
utilization rates among income groups and inmost cases people
pay to get medications.
Comparing the share of health expenditure versus drug ex-
penditure in total household expenditure across income
groups, the analysis of NES depicts the presence of a regressive
pattern for both indicators; also drugs are the main component
for lower income people. So, why do poor people have a biggerconflicts of interest with regard to the content of this article.
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they are very exposed to illness and chances of prevention are
minimal, so they cannot avoid the use of and expense for phar-
maceuticals. This regressive pattern is found for several classes
of drugs. For example, poor people spend a bigger proportion of
health expenditure than rich ones for: 1) fever or pain (57% vs.
32%); 2) cardiac problems (53% vs. 32%); and 3) antibiotics (58%
vs. 38%).
According to NES (1997 vs. 2005), the incidence of cata-
strophic drug expenditure has decreased, especially on the
poorest people (29% in 1997 vs. 17% in 2005). This fact reflects an
improvement on equity of access to pharmaceuticals during
these years. The aim, however, is to achieve equity of access to
treatment. Not onlymedicines; treatment is the composite good
that satisfies needs, and need of health care is central on every
equity criteria on health. Achieving equity of access should not
be thought as a trade-off problem, but instead the real challenge
is to achieve equity in health care access.
In Argentina and within the public sector, improving equity
in access to health care means focusing on: 1) improving capac-
ity, structure, and management, and 2) a generalization of evi-
dence-based practice. The aim of improving equity in access
should be to ensure an adequate program based on a health
technologies assessment (HTA) criteria. Argentina has an ex-
treme need for more transparent policies regarding the uses of
HTA studies. Although there were several actions implemented
by the national health authorities during the past decade, no
one group defines a clear role for HTA. Indeed, in Argentina we
must discuss: 1) the implementation of national/subnational
agencies in charge of HTA and/or the regulation (and/or the
coexistence) of private and independent agencies, and 2) the
formulation of national HTA guidelines.
The problemof access to health care for Argentineans has been
always a matter of perspective. Health systems must center on
equity of access, but we know that partial analysis results in par-
tial results; only by getting the complete picture is it possible to get
full, general, and useful results.
Brazil
Equity in health care, the aim of every health manager, should
begin with a few fundamental concepts. In Latin America there
is a need to establish specific parameters that will underpin the
strategies employed in achieving equity of access to health care.
Brazil, for example, shows very marked differences defined by
demographic factors (access in large cities and in the south of
the country is better than in the north and northeast or in small
towns) as well as economic ones (people with private health
insurance have prompt andmore complete access than patients
who depend on the public system).
To understand this market, an analytic separation can be
made between Brazilians who have private health insurance—
around 40 million people—and the 150 million who depend on
the public system [1]. Even in the private system, the rules of
operation are regulated by the state, which is also responsible
for supervising financial viability within a country. We believe
all health care plans should follow the same rules.
When a health technology is evaluated for adoption and
pricing according to the rules laid down by the Ministry of
Health, the process is practically the same independent of who
will pay in the future. Although it may take longer, this process
is generally complete in 24 months. The product must meet a
series of scientific and economic specifications to be approved
for eventual use in the country. The major differences in pro-
cesses become apparent after this stage.
The model of payment in the public system is basically a
fixed budget based on the disease. For example, if a patient hasbreast cancer and receives first-line treatment, the government
pays a predetermined amount of money and leaves decisions
regarding the appropriate medical protocol to the health care
provider, who works within the value of the reimbursement.
Meanwhile, the private system is maintained on the fee-for-
service model, with remuneration to providers based on a pub-
lished list of prices. Discounts from a supplier to a provider
generate a significant component of the financial result of this
operation. This model is the subject of extensive criticism be-
cause it does not stimulate the optimization of resources [2].
Private operators (health care plans), in turn, use some forms of
analysis with a view to generating criticisms of new proce-
dures when faced with requests for their adoption in health
care. A little of how each of these functions in Brazil is described
here.
Scientific Critical Analysis
The goal of financing institutions is the ideal form of scientific
evidence, represented by meta-analyses and randomized clini-
cal trials. A prescriber, on the other hand, does not always man-
age to provide this level of evidence and, ultimately, he or she
adopts a technology in a less critical way than required by the
financing institution. Several examples of this debate exist. For
example, the use of abstracts, without a thorough analysis of
the full text of articles, as well as interpretations of inappropri-
ately designed studies, represent some of the causes of discus-
sion [3]. The pertinent debate, perhaps, is over the lack of infor-
mation to which the patient has access, which ultimately
creates unrealistic expectations about the results of some treat-
ments. Clinically irrelevant changes may be understood and
used in different ways among the players.
Legal Analysis
According to the law that regulates the operators of health care
plans (known as Law 9656, dating from 1998), drugs that do not
have the necessary approval from the Ministry of Health for a
specific indication are considered off-label and do not need to
be covered by the insurance. Even if the universal application of
this rule is difficult, it is widely used for drugs of high cost. The
tendency is that when there is unequivocal support for the im-
portance of a determined medicine, there is less strictness in
the application of the rule. The arguments over oral drugs, es-
pecially in cancer treatment, continue to grow. It is well known
that very expensive oral drugs will only become a reality if fi-
nancing institutions begin to pay for them. There is very little
experience with pharmaceutical benefit programs in Brazil. In
this scenario there is a great deal of tension and judicial de-
mands and very little useful experience [4].
Pharmacoeconomics Analysis
With strong growth in interest during recent years, this theme
has begun to be addressed by stake-holders in a more profes-
sional way. Although this is still at the stage of defining basic
concepts applicable to the country, there is a strong drive to
broaden the debate, although it remains difficult to translate
these concepts to the bedside in Brazil, as it is throughout the
world [5]. Understanding of the effects on budgets and the need
to create a list of priorities in the allocation of resources is no
longer a theoretical discussion. Suppliers of medicines and de-
vices already recognize that they need to focus on this area and
offer sophisticated subsidies for discussion. The government
fears, however, stimulating growth in this area; financing insti-
tutions have been critical of this and have preferred providers
who are aware of the problem.
So, is equity of access to health care in Latin America achiev-
able? When we invert the current reasoning, which is to distrib-
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system, in such a way that we can define what kind of medicine
we want and, based on this, request a realistic, appropriate
quote, there is a real possibility that we can reduce differences
in our countries.
Colombia
Colombia is one of the few countries in Latin America that has
implemented a nationwide social health insurance program
targeted to the poor. This program, known as the Subsidized
Regime (SR), began to be implemented in 1996 as part of one of
the most ambitious and innovative health care reforms in the
region, enacted by Law 100 in 1993. The reforms sought to im-
prove health outcomes and protect families from the economic
consequences of poor health through mandated social health
insurance coverage for all the population, to increase quality
and efficiency of health care services by introducing competi-
tion in health insurance and health care provision markets and
supply-side reforms, and to augment equity through better tar-
geting of public services.
The SR allocates public subsidies to individual insurance
premiums for the poor according to a proxy-means testing in-
dex. The SR is financed through a combination of resources
obtained from a solidarity contribution from formal workers’
mentioned above, national tax revenues and social invest-
ment transfers to municipalities earmarked for health, and lo-
cal tax revenues. Resources allocated to the SR have reached
considerable amounts, almost 3% of the gross domestic product
in 2009 [6].
The benefits package of the SR emphasizes coverage for pre-
ventive and basic ambulatory care services, and catastrophic
care. Medications within a national listing and medical trans-
portation expenses are also covered. There is no coverage, how-
ever, for specialist care and there are important gaps in cover-
age for hospital care except for some surgical procedures and
orthopedics. Children aged less than 1 year and pregnant
women have almost no restrictions in coverage. There are no
copayments and out-of-pocket expenses are restricted to non-
covered services. The premium for the SR benefits package was
valued at US$142 in 2010.
There is evidence that the SR has contributed to equity im-
provement in several aspects. One of these is health insurance
coverage. The growth of enrollment in the SR has been amazing,
from 0% to almost 51% of the total population in 16 years (1993–
2010). Currently, about 24 million poor people have SR insur-
ance coverage [7]. A key feature of SR insurance has been reach-
ing the peoplemost vulnerable to economic shocks. In 2008, 81%
of the population in the lowest quintiles had health insurance.
A comparison of the proportion of insured individuals by in-
come quintile in 1992 and 2003 shows an increase of 37 percent-
age points or a variation of 444% for the first quintile (9% in 1992
to 48% in 2003), whereas in the fifth quintile the increase was 21
percentage points (60% in 1992 to 81% in 2003 [8]. Rural and
urban disparities in insurance coverage have been progressively
bridged. In 1993 there was a rural–urban insurance coverage
difference of 26% that was reduced by 13 points in 2003, and
health insurance coverage in rural areas currently is mainly at
the expense of the SR.
The SR adds to equity by providing financial protection from
catastrophic health expenditures. Miller et al. [9] found that
compared to uninsured persons, average and large outliers in
health care expenditures in SR enrolees decrease. The SR has
also played a role in poverty alleviation. Household survey data
analyses reveal that between 1997 and 2003 health subsidies
reduced poverty levels and income inequality by more than two
and three percentage points, respectively [10].Quasiexperimental studies have also found that the SR has
made a difference in access and use of services, particularly for
the poor and population in rural areas. For example, Giedion et
al. [11] found that compared to the uninsured, the insured poor
have a 40% higher probability of ambulatory consultations, a
17% higher probability of taking a child with diarrhea to a health
care institution, a 23% higher probability of taking a child with
respiratory infection to a health care institution, and a 7%
higher probability of birth attendance by a health professional
or at a formal institution. Miller et al. [9] also found a higher
likelihood of preventive visits, and of growth monitoring and
well-child visits.
Regarding improvements in equity in health outcomes a few
studies point toward positive results, although on very broad
health indicators. Miller et al. [9] found lower probabilities of
cough, fever, or diarrhea and number of days unable to carry out
daily activities due to illness in children younger than age 5
years covered by the SR. Other research finds that infant mor-
tality decline has been larger amongst the poor, and between
1995 and 2005 overall differentials in infant mortality between
wealth groups slightly decreased, from a 2.5 to a 2.2 times larger
mortality rate in the lower quintiles with respect to the higher
[12]. The latter results, however, do not establish a causal rela-
tionship to the SR.
The Colombian health care reforms, particularly the provi-
sion of health insurance for the poor, have contributed to over-
all equity improvement in financial protection, access to and
use of health services, and in some health outcomes. Neverthe-
less, there is evidence of differentials in these indicators by
sociodemographic and geographic groups, which may re-
quire tailoring health insurance policies to address specific
needs [10].
Further progress is to be expected given that there is a recent
mandate issued by the Colombian Constitutional Court to reach
universal health insurance and to upgrade the breadth and
scope of the SR benefits package in the next years. Implemen-
tation of this policy raises the challenge of designing an effec-
tive package under budget constraints. Health technology as-
sessment can be a key instrument to guide the selection of
interventions to be included in the new package, but Colombia
will need to strengthen both public and private sector
capacity to generate and use economic evaluation for priority
setting.
Mexico
Article four of the Constitution of Mexico [13] clearly states that
all Mexicans have the right to health care, but this has not been
possible due to factors ranging from the purely economic (in-
sufficient resources) to the geographic (communities in remote
areas with difficult access).
Demographically [14], Mexico, as with many countries in the
world, has an increasingly aging population, and with it an in-
crease in prevalence of degenerative chronic diseases, the treat-
ment of which is generally lifelong, thus putting pressure on the
health care budget, which is 5.9% of the gross domestic product.
On the other hand, given the socioeconomic characteristics of
this country, contagious diseases still persist and are common
among the poor, whose treatment is also costly in light of the
need for new generations of antibiotics to address the fact of
ever-increasing bacterial resistance, a product of the self-pre-
scription which for many years was a part of cost containment
for social security.
On one hand, the low health care budget is a result of the
chronic economic crisis with periodic exacerbations that affect
the national economy combined with costly and complicated
administrations. According to numbers from the Organization
S11V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 8 – S 1 2for Economic Cooperation and Development [15], the health ad-
ministration consumes 10% of the budget destined to health
care; thus, a percentage of the health expenditure has fallen
back directly onto families. It is calculated that 3.6% of total
family income goes to health care and from that approximately
43.3% goes to the purchase of medicines.
There are various health care institutions in Mexico, which
together cover 56.2% of the population. Among them is the Mex-
ican Institute of Social Security (IMSS), which covers the major-
ity of social security recipients in Mexico (42.8%), the beneficia-
ries of which are, for the most part, workers in the private
sector. It is an obligatory insurance plan: all employers by law
have to insure their employee(s) via this institution, which is
financed in three ways: 1) contributions from employers; 2) from
federal funds; and 3) by employees who contribute a small part
of their salary.
The Social Security Institute for StateWorkers covers 9.6% of
the population. In this case, the beneficiaries are workers in the
public sector and it is financed with public resources as well as
worker contributions.
The remaining 3.8% is covered by a series of state institu-
tions that function as a captive insurer, which is to say the
beneficiaries of medical coverage are the workers and their fam-
ilies of Mexican Petroleum or government entities with special
characteristics such as the Secretary of National Defense or the
Secretary of the Navy.
The other 43.8% of the population does not have access to
social security and responsibility for this population falls di-
rectly to the Ministry of Health through hospitals, local and
state agencies, and the National Institutes of Health, and is op-
erated by the newly created Popular Insurance, which has
grown rapidly and to which a good amount of resources have
been devoted— mostly for the purchase of medicines and other
health supplies—leaving almost nothing for the infrastructure
of clinics and hospitals. This arrangement functions as an open
health plan in which a beneficiary pays with an extremely low
cost policy (the resources come primarily from the public sec-
tor). The objective is to provide access to services to people who
have established small businesses, working in an informal
economy that once was under the auspice of public hospitals
run by the Secretary of Health. Access to this system is currently
limited to those with the 110 most frequent illnesses and, since
consolidating this system, the Secretary of Health acts only to
guide health policy without providing actual services.
There are other specific programs that have been imple-
mented, such as IMSS Opportunities, directed toward unprotected
populations and funded by public resources.
It is interesting to note that a family can have access to two
systems of health coverage, which is to say, they can be doubly
insured. For example, people can be covered through the Social
Security Institute for State Workers because they have a family
member (e.g., a wife) who works in the public sector and a fam-
ily member (e.g., a husband) has the right to IMSS because he is
employed in the private sector. This creates duplicate access to
health care and also doubles family contributions.
The level of prescriptions dispensed also represents a prob-
lem in the dispensation of medicines in the public sector. A
patient must purchase medicines in pharmacies where the
price is three or four times higher than the original value. On the
other hand, there is no customized system for drug supplies,
which is why the prescribed amount is either insufficient to
complete the treatment indicated or is overly prescribed, result-
ing in a waste of important resources.
Medicines are dispensed in private pharmacies by individu-
als who often have not even received basic education. Some
even make recommendations on products to “alleviate the
symptoms of the patient.” It is not uncommon for pharmacyworkers to change medical prescriptions according to their con-
venience. Pharmacies and commercial centers commonly have
doctors incorporated within stores to see patients; evidently,
prescriptions are made out in favor of the products that the
commercial chain or establishment is selling. Who pays the
costs of complications resulting from these unscrupulous prac-
tices?
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